MyFinsight
Home
Blog
About
Contact
Download
Download image
Sales and maturities
of marketable...
$111,420K
Proceeds from exercise of
stock options
$275K
Net cash provided by
(used in) investing...
$4,556K
Net cash provided by
financing activities
$275K
Canceled cashflow
$106,864K
Net (decrease)
increase in cash and cash...
-$40,819K
Canceled cashflow
$4,831K
Stock-based compensation
expense
$6,449K
Accounts payable,
accrued expenses and...
$929K
Write-off of deferred
financing costs
$230K
Non-cash operating lease
expense
$151K
Purchases of marketable
securities
$106,864K
Net cash used in
operating activities
-$45,650K
Canceled cashflow
$7,759K
Net loss
-$51,038K
Prepaid expenses and
other current assets
$1,830K
Accretion of discount on
marketable securities
$389K
Operating lease
liabilities
-$152K
Back
Back
Cash Flow
source: myfinsight.com
Sagimet Biosciences Inc. (SGMT)
Sagimet Biosciences Inc. (SGMT)